Table 2.
BRCA1 or BRCA2 carriers (N) | Non-carriers (N) | AUC [95% CI] | O/E ratio Pa |
|||
---|---|---|---|---|---|---|
Overall | BRCA1 | BRCA2 | ||||
High-risk breast/ovarian cohort (JHHRCC) | ||||||
BRCAPANCPRO | 85 | 234 | 0.79 [0.73, 0.84] | 0.86 [0.81, 0.91] | 0.64 [0.53, 0.74] | 1.46 [1.22, 1.73] |
P = 0.17 | ||||||
BRCAPRO | 0.77 [0.70, 0.82] | 0.84 [0.78, 0.88] | 0.62 [0.51, 0.73] | 1.42 [1.17, 1.70] | ||
P = 0.26 | ||||||
High-risk pancreatic cancer cohort (PACGENE) | ||||||
BRCAPANCPRO | 28 | 617 | 0.70 [0.60, 0.80] | 0.82 [0.55, 0.98] | 0.69 [0.55, 0.79] | 1.94 [1.26, 3.08] |
P = 0.55 | ||||||
BRCAPRO | 0.71 [0.58, 0.82] | 0.79 [0.48, 0.99] | 0.70 [0.58, 0.82] | 3.07 [1.88, 5.46] | ||
P = 0.10 |
aP value for Hosmer–Lemeshow test for goodness of fit of the model prediction of carrier probability.